An act relating to limiting the reporting of certain medications to the Vermont Prescription Monitoring System
H.581 would amend Vermont’s prescription drug monitoring laws to create an exception for certain controlled substances prescribed for reproductive health care services or gender-affirming health care services. Under the bill, those medications would generally not have to be reported to the Vermont Prescription Monitoring System (VPMS), unless the Commissioner of Health determines that reporting is necessary to protect public health. The bill also directs the state to exclude that information from any data shared through reciprocal agreements with other states’ prescription monitoring programs.
The bill is framed as a privacy and access measure for patients and providers involved in reproductive and gender-affirming care. It would preserve the existing VPMS reporting structure for Schedules II, III, and IV controlled substances, while carving out a specific category of medications tied to protected health services. The effective date is July 1, 2026.
This bill would amend 18 V.S.A. §§ 4283 and 4288, narrowing the scope of mandatory reporting to the Vermont Prescription Monitoring System for certain prescriptions and limiting interstate data sharing. It would affect pharmacies, dispensers, prescribers, patients, and the Department of Health by creating a new reporting exemption and a new restriction on reciprocal disclosure. If enacted, Vermont law would require the Department to keep reproductive-health and gender-affirming-care medication data out of out-of-state prescription monitoring exchanges, unless public-health concerns justify reporting.
No committee transcripts or recorded votes were provided, so there is no documented floor or committee sentiment in the materials. Based on the bill text, the measure appears to be motivated by privacy protections and safeguarding access to reproductive and gender-affirming care, suggesting support from advocates for those services and patient confidentiality. The absence of recorded opposition in the provided materials means the overall political reception cannot be determined from this record alone.
The main point of contention is likely the balance between patient privacy and public-health monitoring. Supporters would likely favor the exemption as a way to protect sensitive medical information and reduce risks associated with disclosure to other states, especially for reproductive and gender-affirming care. Opponents or skeptics may argue that exempting these prescriptions from the VPMS could reduce the system’s usefulness for detecting misuse, diversion, or other safety concerns, which is why the bill preserves a public-health override for the Commissioner of Health.